Portland, OR -- (SBWIRE) -- 06/13/2017 -- Paclitaxel belongs to the group of medications known as antineoplastics and is used in the treatment of cancers. It works by inhibiting the growth of cancer cells and is used in the treatment of various cancers such as breast cancer, ovarian cancer, non small cell lung cancer, etc. According to the WHO, cancer was the leading cause of death worldwide, accounting for the death of 8.2 million people in 2012. The major drivers for this market are the rising incidence of cancer globally and the improved efficacy of paclitaxel injections. However, adverse drug reactions associated with the drug as well as the emergence of targeted treatment, personalized medicine and novel anti-cancer drugs would be a challenge to the growth of this market. The opportunities for this market are its potential to be used for treatment for various types of cancers.
Get full summary of the Report: https://www.alliedmarketresearch.com/paclitaxel-injection-market
The companies in this market are Abraxis Bio Science Inc., Celgene, Abbott Laboratories, Fresenius Kabi Oncology Ltd, Onco therapies Ltd, Novasep, Sagent Pharmaceuticals and others. The European Commission approved ABRAXANE to be taken in combination with Gentamicin for the treatment of metastatic pancreatic cancer in January 2014. ABRAXANE was developed by Celgene International Sàrl, a subsidiary of Celgene Corporation.
Request sample Report: https://www.alliedmarketresearch.com/request-toc-and-sample/287
Paclitaxel Injection Market is segmented by use in treatment of cancer and geography.
Paclitaxel Injection Market by use in treatment of various cancers
- Breast cancer
- Ovarian cancer
- Non small cell lung cancer
- AIDS related Kaposi's sarcoma
- Cervical Cancer
- Esophageal cancer
- Prostate cancer
- Stomach cancer
- Testicular cancer
- Lung cancer
- Pancreatic cancer
Paclitaxel Injection Market by Geography
- North America
- Asia Pacific